Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Working Capital Changes (2019 - 2025)

Historic Other Working Capital Changes for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$1.8 million.

  • Keros Therapeutics' Other Working Capital Changes rose 6899.37% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 6911.1%. This contributed to the annual value of $10.2 million for FY2024, which is 1004.95% up from last year.
  • Keros Therapeutics' Other Working Capital Changes amounted to -$1.8 million in Q3 2025, which was up 6899.37% from $2.5 million recorded in Q2 2025.
  • Keros Therapeutics' Other Working Capital Changes' 5-year high stood at $6.4 million during Q2 2024, with a 5-year trough of -$5.9 million in Q3 2024.
  • Over the past 5 years, Keros Therapeutics' median Other Working Capital Changes value was $521000.0 (recorded in 2021), while the average stood at $1.1 million.
  • Over the last 5 years, Keros Therapeutics' Other Working Capital Changes had its largest YoY gain of 158432.06% in 2023, and its largest YoY loss of 29962.96% in 2023.
  • Over the past 5 years, Keros Therapeutics' Other Working Capital Changes (Quarter) stood at -$1.3 million in 2021, then surged by 120.35% to $270000.0 in 2022, then plummeted by 299.63% to -$539000.0 in 2023, then soared by 1073.28% to $5.2 million in 2024, then plummeted by 134.71% to -$1.8 million in 2025.
  • Its Other Working Capital Changes stands at -$1.8 million for Q3 2025, versus $2.5 million for Q2 2025 and -$4.5 million for Q1 2025.